What is the appropriate management for a patient with an atrial septal defect and atrioventricular valve regurgitation?

Management of Atrial Septal Defect with Atrioventricular Valve Regurgitation

Patients with ASD and significant atrioventricular valve regurgitation (AVVR) require surgical repair rather than isolated ASD closure, with timing dictated by the severity of valve regurgitation, right ventricular dilation, and pulmonary artery pressure—not by ASD hemodynamics alone.

Initial Diagnostic Assessment

Hemodynamic Evaluation

• Measure the Qp:Qs ratio to quantify left-to-right shunting; a ratio ≥1.5:1 with right atrial and RV enlargement indicates hemodynamically significant shunting 1
• Assess pulmonary artery systolic pressure; levels >50% of systemic pressure or pulmonary vascular resistance >1/3 systemic resistance warrant careful evaluation before any intervention 1
• Critical contraindication: Do not close the ASD if PA systolic pressure exceeds two-thirds systemic pressure, pulmonary vascular resistance exceeds two-thirds systemic resistance, or a net right-to-left shunt exists 1

Valve and Ventricular Assessment

• Quantify AVVR severity using effective regurgitant orifice area, vena contracta width, and color-Doppler imaging 2
• Measure RV dimensions and systolic function; RV dilation or dysfunction mandates surgical consideration 2
• Evaluate tricuspid annular diameter; >40 mm (or >21 mm/m²) indicates significant annular dilation requiring surgical attention 2
• Perform pulse oximetry at rest and with exercise to identify shunt reversal or desaturation <90% with activity 1

Anatomic Imaging

• Obtain transesophageal echocardiography or cross-sectional imaging (CMR/CCT) to define atrial septal anatomy, pulmonary venous connections, and valve morphology—transthoracic echo has limited visualization of the superior and posterior atrial septum in adults 1
• Identify valve cleft location and morphology; a regurgitant jet centered around the cleft (rather than central) predicts progression to severe regurgitation and need for reoperation 3
• Screen for additional left atrioventricular valve malformations, which occur in approximately 30% of cases and independently predict mortality 4

Management Strategy Based on AVVR Severity

Mild AVVR with Hemodynamically Significant ASD

• Proceed with percutaneous or surgical ASD closure when Qp:Qs ≥1.5:1 and right heart enlargement is present without cyanosis 1
• Surveillance echocardiography every 6–12 months to monitor for valve regurgitation progression 2
• Optimize guideline-directed medical therapy for any coexisting left ventricular dysfunction 2

Moderate AVVR

• Do not perform isolated ASD closure; moderate AVVR after or concurrent with ASD is linked to 17% mortality and 45% progression to severe regurgitation within a median of 2 months 3
• Observe for up to 1 year if the regurgitant jet is centrally located, as regurgitation remains stable in 26% and improves to mild in 29% of patients 3
• If the jet is centered around a cleft, the odds ratio for progression to severe regurgitation and reoperation is 3.5, mandating closer surveillance or earlier surgical intervention 3
• Refer to a multidisciplinary Heart Team at a comprehensive valve center for surgical planning 2

Severe AVVR

• Immediate surgical referral is mandatory before the onset of severe RV failure or irreversible end-organ damage 2
• Surgical repair includes ASD patch closure (autologous pericardium preferred), complete cleft closure in >90% of cases, and individualized valvuloplasty techniques 4
• Consider annuloplasty (flexible ring or incomplete band) in 21–32% of patients with significant annular dilation 4, 5
• Valve replacement is reserved for cases with myxomatous degeneration or failed repair attempts 6

Surgical Timing and Technique

Optimal Timing

• Operate before development of severe RV dysfunction, pulmonary vascular obstructive disease, or liver cirrhosis—these conditions markedly increase surgical risk and are linked to poor outcomes 2, 7
• In complete AVSD, early repair (ideally age <3 months) is preferred over pulmonary artery banding, as prior banding is an independent predictor of long-term mortality 8
• For partial AVSD in adults, median age at repair is 23.7 months, but surgery can be performed safely even in elderly patients (reported up to age 79) 9, 5

Surgical Approach

• Perform detailed intraoperative assessment of valve morphology; grossly malformed left atrioventricular valve apparatus is an independent predictor of death (odds ratio 38.92) 4
• Close the cleft completely in >92% of cases; partial cleft closure is an independent risk factor for mortality (hazard ratio 2.43) 10
• Address concomitant lesions: left ventricular outflow tract obstruction occurs in a significant proportion and should be evaluated intraoperatively 11, 10
• Measure tricuspid valve tethering height; >8 mm predicts recurrent TR after repair 2

Postoperative Surveillance and Complications

Early Postoperative Period

• Perform comprehensive echocardiography to assess residual AVVR; moderate or greater regurgitation immediately postoperatively is an independent risk factor for reoperation (hazard ratio 2.6) 10
• Screen for residual atrial or ventricular septal defects; presence of residual cardiac defects doubles the risk of reoperation (hazard ratio 2.0) 10
• Monitor for supraventricular arrhythmias, which occur in 11–91% of patients depending on complexity 4, 5

Long-Term Follow-Up

• Freedom from reoperation is 78.2% at 10 years, 75.8% at 15 years, and 72.5% at 25 years 10
• The main indication for reoperation is left atrioventricular valve regurgitation (86% of reoperations), though 36% of procedures address multiple lesions 10
• Survival is 88.3% at 10 years, 83.8% at 15 years, and 79.6% at 25 years in contemporary series 5
• Measure B-type natriuretic peptide levels to assess disease severity and guide therapeutic adjustments 2

High-Risk Features Requiring Intensive Monitoring

• Preoperative pulmonary artery hypertension increases mortality risk 6.88-fold 4
• Absence of Down syndrome paradoxically increases reoperation risk, likely due to more complex valve pathology 8
• Prematurity (hazard ratio 2.43) and low weight <4 kg (hazard ratio 3.05) are independent mortality risk factors 10
• Patients without Down syndrome and those with moderate LAVVR on postoperative echocardiography require particularly close surveillance 8, 3

Pitfalls to Avoid

• Never perform isolated percutaneous ASD closure in the presence of moderate or severe AVVR; this ignores the primary pathology driving morbidity and mortality 3
• Do not delay referral until symptoms develop; asymptomatic patients with severe AVVR and RV dilation benefit from earlier intervention to prevent irreversible RV injury 2
• Avoid incomplete cleft closure, as this independently predicts mortality 10
• Do not overlook atrial fibrillation, which exacerbates functional TR and requires rhythm control or anticoagulation 2